SAREPTA THERAPEUTICS, INC. Proceeds from Long-Term Debt Issued
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2023-02-28
- SAREPTA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- SAREPTA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2020 was $291.15M, a 18.53% increase from fiscal 2019.
- SAREPTA THERAPEUTICS, INC. proceeds from issuance of long-term debt for fiscal 2019 was $245.63M.
| Period end | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2020-12-31 | $291.15M 10-K · filed 2023-02-28 |
| 2019-12-31 | $245.63M 10-K · filed 2022-03-01 |
| 2017-12-31 | $30.00M 10-K · filed 2019-02-28 |
| 2015-12-31 | $20.00M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |